Graziella Pellegrini is Full Professor and Head of the Cell Therapy Program at Centre for Regenerative Medicine "Stefano Ferrari" of the University of Modena and Reggio Emilia. She is also co-founder and R&D Director at Holostem Terapie Avanzate S.r.l., having developed Holoclar®, the world's first commercial stem-cell therapy.
She was awarded for research on central nervous system, on burn patients, for research on ocular pathology and for research on urethra. (Author of several international patents, book chapters and many peer reviewed publications in the major international scientific journals, she was invited speaker or chairman in over two hundreds major international meetings and courses on Stem Cells and Regenerative medicine.)
Prof. Pellegrini is one of the two inventors of the technology for culture, and transplantation of limbal stem cells for treatment of blindness due to corneal stem cell deficiency, and defended the orphan drug designation and European registration of the therapy. She is currently collaborating to a phase I clinical trial on gene therapy of epidermolysis bullosa.
Iris Jonkers is Assistant professor and Rosalind Franklin Fellow at the Department of Genetics, University Medical Center Groningen, in the Netherlands. Her research focus is the elucidation of the role of the genetic risk factors in Celiac Disease and a better understanding of how genetics contribute to disease.
How other genetic risk factors rather than the HLA-DQ2.5 and HLA-DQ8 contribute to coeliac disease is not well understood, as the changes in DNA primarily fall within the non-coding genome. In order to better understand these changes, her laboratory takes several approaches at multiple levels. Taken together, these aim to elucidate which molecular pathways are affected by genetics in CeD and to identify potential drug targets to treat this disease.
Currently, Professor Jonkers is studying how small changes in DNA enriched in celiac patients influence the regulation of gene expression and lead to celiac disease. To answer this question, she has received a Rosalind Franklin Fellowship and a Dutch VIDI-NOW grant.
Derek Perkins, Ph.D. is a Consultant Clinical & Forensic Psychologist at West London Mental Health NHS Trust, Professor of Forensic Psychology at Royal Holloway University of London, Co-director of the onlineProtect research group on internet-related sexual offending, and a Trustee of the Lucy Faithfull Foundation. He was Head of Psychological Services at Broadmoor Hospital (high secure psychiatric hospital) from 1986-2013, having previously worked in the UK Prison Service and Midland Centre for Forensic Psychiatry. He has worked in secure and community settings on the assessment and treatment of sex offenders, the interface between mental disorder and sexual offending, psychophysiological assessment of sexual interest, child sexual exploitation and sexual homicide.
Klaus M. Beier studied medicine and philosophy. He is a specialized physician for psychosomatics and psychotherapy and is head of the Institute of Sexology and Sexual Medicine at the Charité – Universitätsmedizin Berlin. He is in charge of the undergraduate training of medical school students in sexual medicine as well as the postgraduate training for physicians and psychologists in this field. He is also responsible for the Outpatient Clinic of the Institute which offers assessment and treatment for the full range of sexual disorders and gender dysphoria.
His main focus in research is the prevention of child sexual abuse. The goal is to encourage self-identified undetected pedophiles to seek professional help in order to avoid committing child sexual abuse or the use of child abuse images. For this purpose, in 2005 he initiated the “Prevention Project Dunkelfeld” which has now extended to 10 additional locations all over Germany. Furthermore, in 2017 he started the internet-based self-management tool “Troubled Desire” for assessment and treatment in case of pedophilia to prevent child sexual abuse.
Regarding these efforts, in 2017, he was awarded the Order of Merit from the Federal Republic of Germany.
Dr. Chandan K Sen is a tenured John H & Mildred C Lumley Professor of Surgery, Executive Director of The Ohio State University Comprehensive Wound Center and Director of the Ohio State University's Center for Regenerative Medicine & Cell Based Therapies. He is also the Associate Dean for Industry Partnership at The Ohio State University Wexner Medical Center. After completing his Masters of Science in Human Physiology from the University of Calcutta, Dr. Sen received his PhD in Physiology from the University of Eastern Finland (Kuopio). Dr. Sen trained as a postdoctoral fellow at the University of California at Berkeley's Molecular and Cell Biology department. His first faculty appointment was in the Lawrence Berkeley National Laboratory in California.
In fall of 2000, Dr. Sen moved to The Ohio State University where established a program on tissue injury and repair. Currently, Dr. Sen is a Professor and Vice Chair of Research of Surgery. A major focus on Dr. Sen's research is to induce tissue plasticity in vivo. He and his collaborators have developed the Tissue Nanotransfection (TNT) technology which was published in Nature Nanotechnology in 2017 and won the 2018 Edison Award for medical innovation. Dr. Sen and his team have published over 300 scientific publications. He has a H-index of 86 and is currently cited over 2100 times every year for a total of over 28000 times.
Dr Maher is Coordinator, Research Capacity Strengthening, at the Special Programme for Research and Training in Tropical Diseases. He is based in Geneva where TDR is hosted by the World Health Organization (WHO). He trained in medicine in the United Kingdom at Cambridge and Oxford, with subsequent postgraduate training in family medicine, internal medicine and infectious diseases.
He was a specialist physician in Malawi, a TB medical officer with WHO in Geneva, head of a programme of HIV research in Uganda with the Medical Research Council (UK) and Uganda Virus Research Institute, Senior TB Advisor with the Global Fund to Fight AIDS, Tuberculosis and Malaria in Geneva and International Portfolio Manager at the Wellcome Trust in London.
His professional qualifications are in family medicine, general medicine and public health, and he has a doctorate in public health. He has broad experience in research in developing countries, particularly in TB, HIV and non- communicable diseases. His research expertise is in the following areas: clinical research, operational research, epidemiology, research methodology, health systems research (particularly the links between research and policy) anethics. His main current interest is in strengthening research capacity in low- and middle-income countries.
Ishwar Singh is Senior Lecturer in biological chemistry at the School of Pharmacy, University of Lincoln. Prior to Lincoln, he had held many prestigious fellowships such as the Alexander von Humboldt fellowship, Germany; and Senior Research Fellowship, DANIDA, Denmark and CSIR, India. He has 20 years' experience in Organic Chemistry focusing on Antimicrobials, Bioconjugations, Biologics Delivery, Nucleic Acids and Peptide modifications. He is currently leading research in novel antimicrobials based on rational design against clinically important resistant pathogens (such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, Mycobacteria, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa), biologics delivery, peptides, sequence-selective DNA cross linking, nanoparticles modifications for drug delivery and diagnostic applications.
He has pioneered the efficient synthesis and first SAR of teixobactin analogues (Chem. Comm. 2016, 6060). He has led the seminal study that determined the 3-dimensional structures of teixobactin analogues and identified the critical residues required for biological activity (Chem. Comm. 2017, 2016,). He has developed potent analogues of teixobactin against MRSA (Chem. Comm. 2017, 7788, featured in "Chemistry World, 7 July 2017). He has published an invited viewpoint article on texiobactins (ACS Infect Dis 2017, 3 (10), 688-690). He has pioneered a simplified design and an efficient synthesis of highly potent teixobactin analogues against MDR Gram positive bacteria such as MRSA and VRE (Chemical Science 2017, 8, 8183-8192). Many of these analogues showed highly potent activity against S aureus, MRSA and VRE in vitro and in vivo (J Med Chem, 2018).
Lorna Role is currently a SUNY Distinguished Professor and Chair of the Department of Neurobiology & Behavior, at the School of Medicine at Stony Brook University. In addition, she is co –director of the Hartman Center for Parkinson’s Disease Research co-director of the Neurosciences Institute.
Her core scientific question is “What are the mechanisms by which cholinergic signaling modulates synapses, circuits and networks that underlie emotional memories and behaviors?” (e.g. memories associated with strong aversive or appetitive stimuli). The potential translational relevance of Dr. Role’s work includes understanding the fundamental biology of disorders that involve alterations in cholinergic signaling including addiction, early development and continued maintenance and plasticity of cholinoceptive networks, exacerbated cued memory behaviors and cognitive decline.
In collaboration with a spectacular array of students and postdocs, her laboratory helped bring to prominence the role of presynaptic, ligand-gated ion channels as potent modulators of synaptic transmission and of axonal nAChRs, in particular, as an important site of action for acetylcholine and nicotine. Their studies of molecular regulators of neuronal nAChRs led to the identification of a novel splice isoform of the neuregulin 1 gene – long considered a prominent candidate susceptibility gene for schizophrenia. Dr. Role’s current research aims to dissect the role of cholinergic signaling in the inscription and retention of memories, with particular emphasis on how acetylcholine contributes to the effects of highly salient experiences on learning and memory.
Qualified as a medical doctor at Copenhagen University Medical School in 2001 and currently holds an Academic Clinical Lectureship in Psychiatry at Imperial College London. Alongside his clinical training in medicine/psychiatry, David has been involved in psychopharmacological research, using brain-imaging techniques such as PET and MRI. Initially working at Columbia University in New York, he then undertook a PhD at University Hospital Rigshospitalet in Copenhagen.
Since 2009, under the mentorships of Profs Anne Lingford-Hughes and David Nutt at Imperial College London, he has conducted post-doc imaging research in the neurobiology of addictions and major depression. Together with Prof Nutt and Dr Carhart-Harris he is also investigating the neurobiology and therapeutic potential of MDMA and classic psychedelics.
Michel D. Ferrari is Professor of Neurology and Chair of the Leiden Centre for Translational Neuroscience at Leiden University Medical Centre, President of the Dutch Headache Society, and past President of the International Headache Society. He received his MD, his specialty certificates in Neurology and Clinical Neurophysiology and his PhD on “Serotonin and Migraine” from LUMC.
Ferrari serves and has served on the executive, scientific and advisory boards of many scientific organisations, is Associate Editor of Cephalalgia and Headache Currents, Senior Associate Editor of Headache, and a regular peer reviewer for high ranking scientific journals.
His research focuses on the neurobiological, genetic, clinical, epidemiological and therapeutic aspects of “Paroxysmal Cerebral Disorders”, in particular migraine, cluster headache, episodic ataxia, and epilepsy. Ferrari ranks among the global top three most cited scientists on “Migraine and Other Vascular Headaches”. His landmark paper on the first migraine gene (Cell 1996) is the highest cited paper in the field. In 2011, he was awarded the triennial Hartmann Muller Prize for Biomedical Research from the University of Zurich and with the Spinoza LifeTime Achievement Premium (2009), the highest science prize in The Netherlands.
After obtaining the specialist diploma in Plastic Surgery, Dr Barret worked at the University of Texas Medical Branch, Galveston, Texas, USA where he developed a clinical research career and obtained a Master’s Degree in Clinical Research. He also worked at the University Hospital Groningen in the Netherlands, where he obtained his PhD degree and at the St Andrews Centre for Plastic Surgery and Burns in the UK. He returned to Barcelona in 2004 and he was appointed Head of Department and Professor of Surgery.
His clinical interests include reconstructive microsurgery, burn surgery and reconstruction, facial palsy and facial reconstruction, Face Transplantation (in 2010 he performed the world’s first full face transplant) and regenerative medicine.The research focus of Dr Barret includes Composite Tissue Allotransplantation, Regenerative Medicine including adult stem cell therapies and 3D bioprinting and bioinformatics/digital technology.
Miss Rozina Ali is an highly trained and experienced consultant plastic, reconstructive and aesthetic surgeon, with a special interest in all aspects of breast surgery. Having graduated from St Thomas' Hospital Medical School with first class BSc honours in 1992, Miss Ali went on to pursue postgraduate surgical training at several London teaching hospitals, as well as specialist units such as the Cranio-facial Unit at Great Ormond Street and the Burns unit at Billericay/Chelmsford.
In 2004, Miss Ali won the prestigious Kroll scholarship to study microvascular breast reconstruction in Belgium and in 2007 she was awarded a 1 year international microsurgery fellowship in Taiwan. Since that time she has enhanced her training with travels to Japan, Australia and China. Miss Ali has been awarded a British Association of Aesthetic Plastic Surgeons (BAAPS) European scholarship and the Cutler's Surgical Fellowship. She has published and presented extensively on microvascular surgery and reconstructive breast surgery both nationally and internationally.